Study on a Prosthetic Foot With Adjustable Heel Height
ADJUST
Impact of a Prosthetic Foot With Adjustable Heel Height on Physical Appearance and Participation: a Randomized Crossover Trial.
1 other identifier
interventional
30
1 country
5
Brief Summary
Most prosthetic feet have a fixed heel height, which requires users to always wear shoes with the same heel height. A fixed heel height is a significant constraint, whereas the ability to choose one's clothing freely is an important aspect of coping with a physical disability. The Taleo Adjust is a prosthetic foot with a hydraulic ankle that allows the user to adjust the heel height from 0 to 7 cm, depending on the type of shoe worn. This study aims to evaluate the impact of an adjustable-heel-height foot on physical appearance and participation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2025
Shorter than P25 for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2025
CompletedStudy Start
First participant enrolled
October 8, 2025
CompletedFirst Posted
Study publicly available on registry
October 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 6, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 6, 2026
November 25, 2025
November 1, 2025
8 months
September 23, 2025
November 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prosthetic Evaluation Questionnaire - Appearance scale (PEQ-AP)
A 5-item self-reported measure of the appearance domain. The participant rates each item by marking a 100-mm line. Scores range from 0 to 100, with higher scores indicating a more positive perception.
30 days
Secondary Outcomes (7)
Patient Specific functional Scale (PSFS)
30 days
Psychosocial Impact of Assistive Device Scale (PIADS)
30 days
Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)
30 days
Visual Analog Scale (VAS) for the adequacy to life's project
30 days
EuroQuol - 5 Dimensions - 5 Levels (EQ-5D-5L)
30 days
- +2 more secondary outcomes
Study Arms (2)
Taleo Adjust foot then usual foot
OTHERThe participant is first fitted with the Taleo Adjust foot for 30 days, then is fitted with their usual foot for 30 days.
Usual foot then taleo Adjust foot
OTHERThe participant is first fitted with their usual foot for 30 days, then fitted with the Taleo Adjust foot for 30 days
Interventions
The Taleo Adjust foot is an energy-storage-and-return (ESR) prosthetic foot with a hydraulic ankle joint that allows an adjustable heel height from 0 to 7 cm.
The usual foot of the participant is an Energy Storage and Return (ESR) prosthetic foot (no heel height adjustement)
Eligibility Criteria
You may qualify if:
- Adult patient with a major lower limb amputation whose life project includes:
- movement in buildings other than the home (ICF d4601),
- movement outside the home and other buildings (ICF d4602),
- and other specified activities related to movement in other various places (ICF d4608).
- Patient who has been using an Enregy storage and Return (ESR) foot for at least 3 months
- Patient who wishes to walk with shoes with different heel heights, and/or barefoot
You may not qualify if:
- Patient with a high impact level (e.g.: sport)
- Patient with hip disarticulation or equivalent
- Patient with an unstabilised residual limb and/or an unsuitable socket
- Patient who cannot be fitted with a Taleo Adjust foot due to the technical characteristics of the product (user weight greater than 115kg; required foot size \<22 or \>28; mounting height less than 118 mm)
- Patient whose usual foot has a heel height adjustment system
- Patient unavailable for the duration of the study and/or unable to understand the instructions and/or answer questionnaires in French
- Patient already participating in another study
- Patient in an emergency situation or pregnant woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
CH Cornouaille
Concarneau, France
CHU Grenoble
Échirolles, France
IRR Louis Pierquin
Nancy, France
CRRF La Tourmaline
Saint-Herblain, France
Institut Merle d'Aubigné
Valenton, France
Study Officials
- STUDY CHAIR
Brice LAVRARD, Dr.
Institut Merle d'Aubigné - VALENTON
- STUDY CHAIR
Isabelle LOIRET
IRR Louis Pierquin - NANCY
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2025
First Posted
October 9, 2025
Study Start
October 8, 2025
Primary Completion (Estimated)
June 6, 2026
Study Completion (Estimated)
June 6, 2026
Last Updated
November 25, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share